A multiplex PCR test for the detection of winter viruses including SARS-CoV-2, influenza A and B, and RSV
Genedrive PLC (AIM:GDR) US FDA pre-submission for Genedrive MT-RNR1 kit
Genedrive file US FDA Pre-Submission for the Genedrive ® MT-RNR1 Product Range
Genedrive PLC (AIM:GDR) NICE includes Genedrive CYP2C19-ID Kit in new Diagnostics Assessment Programme
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (‘NICE’) has commenced an evaluation of CYP2C19 genotype testing for
Novacyt S.A. (AIM:NCYT) Launch of research-use-only adenovirus F41 assay
The assay has been developed by Novacyt to support research efforts following a recent increase in cases of acute hepatitis in children
Novacyt S.A. (AIM:NCYT) Approval of exsigT COVID-19 Direct test in the UK
Approval of exsig™ COVID-19 Direct test in the UK under CTDA legislation
Novacyt S.A. (AIM:NCYT) Trading update and progress against strategy
Trading update and progress against strategy for H1 2022
Oxford BioDynamics (AIM:OBD) US reimbursement code for EpiSwitch® CiRT
Issued US reimbursement code for Checkpoint Inhibitor Response Test (EpiSwitch® CiRT)
Novacyt S.A. (AIM:NCYT) Launch of monkeypox assay
Paris, France and Camberley, UK – 28 June 2022 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces the launch of its research-use-only
Novacyt S.A. (AIM:NCYT) DHSC dispute update
Paris, France and Camberley, UK – 16 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with
Genedrive PLC (AIM:GDR) Point-of-Care COV19-ID Kit receives CTDA approval
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK Medicines and Healthcare Products Regulatory Agency has granted a CTDA enabling the sale of the Genedrive®
Novacyt S.A. (AIM:NCYT) DHSC dispute update
Paris, France and Camberley, UK – 26 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with
